【摘要】 [目的]比较胺碘酮和莫雷西嗪治疗冠心病心肌缺血患者室性心律失常的疗效。[方法]80例冠心病心肌缺血合并室性心律失常患者,均接受冠心病正规治疗,其中40例同时口服胺碘酮片(胺碘酮组),40例口服莫雷西嗪片(莫雷西嗪组),疗程4周。疗程开始及结束时均行24h动态心电图及12导联心电图检查。[结果]两组患者用药后24h室性早搏、短阵室性心动过速的发作次数均明显减少,胺碘酮组用药后与用药前比较分别为(7438±3940)个和(1924±1126)个,(10.82±4.61)次和(2.38±1.24)次;莫雷西嗪组则分别为(7122±3375)个和(3886±1687)个,(10.60±3.92)次和(4.89±2.18)次,P均﹤0.05。胺碘酮组的疗效高于莫雷西嗪组(P﹤0.01)。两组均未见严重副作用。[结论]胺碘酮对冠心病伴室性心律失常的疗效优于莫雷西嗪。更多还原

【Abstract】 [Objective] To investigate the effect and safety of amiodarone and moricizine on ventricular arrhythmias (VA) in patients with coronary heart diseases (CHD). [Methods] 80 CHD patients with VA were randomly divided into 2 groups.40 patients were given with amiodarone (amiodarone group) and 40 patients were given moricizine (moricizine group). [Results] In both groups, the occurrences of ventricular arrhythmias were reduced sharply.Premature ventricular beats and paroxysmal ventricular tachycardias before and after treatment in amiodarone group were (7438 ± 3 940, 1 924 ± 1 126) , (10.82 ± 4.61, 2.38 ± 1.24) respectively (P﹤0.05). And in moricizine group were respectively (7 122 ± 3 375, 3 886±1 687), (10.60±3.92, 4.89±2.18)(P﹤0.05). The effect of amiodarone was better than moricizine (P﹤0.01). No heart function deterioration occurred in both group. [Conclusion] Amiodarone is effective on VA in patients with CHD and more effective than moricizine.更多还原